Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study.
Kim A PappMark G LebwohlDiamant ThaҫiJanusz JaworskiBartlomiej KwiekJakub TreflerAnna DudekJacek Cezary SzepietowskiNataliya ReznichenkoJoanna NarbuttWojciech BaranJoanna KolinekStefan DanilukKatarzyna Bartnicka-MaslowskaAdam ReichYuriy AndrashkoSunghyun KimYunju BaeDabee JeonJinsun JungHyunseung LeeTina PyoWoori KoPublished in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2023)
ClinicalTrials.gov Identifier: NCT04673786; date of registration: 17 December, 2020.